drugset / Trial / NCT00156208

Safety of Treatment of Uterine Fibroids With Asoprisnil

NCT00156208

Phase 3 Completed 166 enrolled Abbott
Non-randomizedParallel-groupSingle-blindTreatment

Summary

The objective of this study is to determine the long-term safety of asoprisnil in women with symptomatic uterine fibroids who completed the 6 month Study C02-037.

Timeline

Start
2004-04
Primary completion
2006-12
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Asoprisnil Other / unclassified 10 mg Oral
Subject Asoprisnil Other / unclassified 25 mg Oral